Exelon Approved For Parkinson’s Dementia
FDA approved Novartis' Exelon (rivastigmine) June 27 for treatment of mild to moderate dementia related to Parkinson's disease
FDA approved Novartis' Exelon (rivastigmine) June 27 for treatment of mild to moderate dementia related to Parkinson's disease